Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
New emerging targets in cancer immunotherapy: the role of neoantigens.
Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control.
Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC.
IL7RA rs6897932 Polymorphism is Associated with Better CD4 + T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy.
Evolution of the gut microbiome following acute HIV-1 infection.
Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunesupression.
HIV-1 Nef Targets HDAC6 to Assure Viral Production and Virus Infection.
Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals.